Tranexamic Acid Use in Cancer Patients
Introduction to Tranexamic Acid in Cancer Care
- The International Society on Thrombosis and Haemostasis states that tranexamic acid is not recommended for routine use in cancer-associated disseminated intravascular coagulation (DIC) and may be deleterious in non-hyperfibrinolytic types 1
- The American Society of Anesthesiologists recommends considering tranexamic acid in major cancer surgery with anticipated massive blood loss, using standard trauma dosing: 1g IV over 10 minutes followed by 1g infusion over 8 hours 2, 3
Specific Scenarios for Tranexamic Acid Use
- Tranexamic acid may be considered in cancer patients undergoing major cancer surgery with anticipated massive blood loss, such as extensive pelvic exenteration or hepatobiliary resections, using standard trauma dosing 2, 3
- The American College of Surgeons suggests that tranexamic acid can be used in postoperative bleeding in cancer patients when excessive bleeding occurs after surgery, administered within 3 hours of bleeding onset for maximum efficacy 4
- Tranexamic acid may only be considered in hyperfibrinolytic DIC when therapy-resistant bleeding dominates the clinical picture, as a last-resort measure after all other interventions have failed 1
Critical Safety Considerations
- The International Society on Thrombosis and Haemostasis notes that cancer patients often have baseline hypercoagulability, making the thrombotic risk profile different from trauma or surgical patients 1
- Patients with active intravascular clotting or DIC should never receive tranexamic acid as it may worsen the condition 1, 6
- The National Kidney Foundation recommends dramatic dose reduction to 10 mg/kg every 48 hours maximum in patients with severe renal impairment to prevent neurotoxicity and seizures 5